Show simple item record

dc.contributor.authorvon Moos, R
dc.contributor.authorHawle, H
dc.contributor.authorHayoz, S
dc.contributor.authorCathomas, R
dc.contributor.authorMuller, A
dc.contributor.authorSchmid, S
dc.contributor.authorPagani, O
dc.contributor.authorWehrhahn, T
dc.contributor.authorRauch, D
dc.contributor.authorAnchisi, S
dc.contributor.authorHermanns, T
dc.contributor.authorFehr, M
dc.contributor.authorStoll, S
dc.contributor.authorButzberger, P
dc.contributor.authorZweifel, M
dc.contributor.authorHuber, U
dc.contributor.authorFuhrer, AC
dc.contributor.authorSchar, C
dc.contributor.authorGillessen, Silke
dc.contributor.authorTempleton, AJ
dc.date.accessioned2019-04-29T09:48:53Z
dc.date.available2019-04-29T09:48:53Z
dc.date.issued2018en
dc.identifier.citationvon Moos R, Hawle H, Hayoz S, Cathomas R, M�ller A, Schmid S, et al. 1703P Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of Oncology. 2018;29(suppl_8).en
dc.identifier.pmidNo PMIDen
dc.identifier.doi10.1093/annonc/mdy300.020en
dc.identifier.urihttp://hdl.handle.net/10541/621734
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy300.020en
dc.titleIncidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Oncology/Hematology, Kantonsspital Graub�nden, Chur, Switzerlanden
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T12:33:33Z


Files in this item

Thumbnail
Name:
561586.pdf
Size:
109.2Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record